DEX oral gavage PK raw data. by Kavya Annu (11587215)

Discontinuous DEX PK raw data from repeated study. by Kavya Annu (11587215)

Cartoon depicting dexamethasone and dasatinib metabolism and efflux transport in intestine and liver. by Kavya Annu (11587215)

Gene expression (qPCR) data from livers of C57BL/6 mice before and after DEX treatment. by Kavya Annu (11587215)

Raw data from survival study in VD₃ sufficient vs. deficient male mice from BCR-ABL ALL when treated with dexamethasone. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient hCYP3A4 12-week-old mice liver and kidney. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient C57BL/6 mice duodenum. by Kavya Annu (11587215)

Gene expression (qPCR) data from duodenums of C57BL/6 mice before and after DEX treatment. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient hCYP3A4 12-week-old mice duodenum. by Kavya Annu (11587215)

Kaplan-Meier curves for the effect of VD₃ sufficiency vs. deficiency on survival of mice from BCR-ABL Arf-/- leukemia. by Kavya Annu (11587215)

Cyp and transporter gene expression in liver and kidney of 12-week-old hCYP3A4 mice. by Kavya Annu (11587215)

Differences in plasma and gut dexamethasone concentrations following the oral discontinuous DEX regimen leads to tissue specific activation of GCR and PXR. by Kavya Annu (11587215)

Cartoon depicting hypothesis that dexamethasone-activated PXR can induce Cyp3a in VD₃ deficient mice, but not in VD₃ sufficient mice where 1,25(OH)<sub>2</sub... by Kavya Annu (11587215)

Cyp and transporter gene expression in duodenum of VD₃ sufficient and deficient mice. by Kavya Annu (11587215)

Dexamethasone plasma pharmacokinetics in male and female VD₃ sufficient and deficient mice, aged 14 weeks, after a single oral gavage of 2 mg/kg dexamethasone phosphate. by Kavya Annu (11587215)

Dasatinib plasma pharmacokinetics in male and female VD₃ sufficient and deficient mice after a single oral gavage of 10 mg/kg dasatinib. by Kavya Annu (11587215)

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”